Biomarker of the colorectal cancer in inflammatory bowel decease patients.

2015 Fiscal Year Final Research Report

• Project/Area Number: 26670598
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Digestive surgery
• Research Institution: The University of Tokyo
• Principal Investigator: SUNAMI EIJI 東京大学, 医学部附属病院, 登録研究員 (70345205)
• Co-Investigator(Kenkyū-buntansha): ISHIHARA SOICHIRO 東京大学, 医学部付属病院, 講師 (00376443) ; YAMAGUCHI HIRONORI 東京大学, 医学部付属病院, 登録研究員 (20376445) ; WATANABE TOSHIAKI 東京大学, 医学部付属病院, 教授 (80210920)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: 炎症性腸疾患 / 大腸がん / バイオマーカー

Outline of Final Research Achievements

Inflammatory Bowel decease (IBD) may cause colorectal cancer after long disease duration. In this study, the possibility of early detection of the colorectal cancer by means of the blood, feces and biopsy is investigated. In this study, we quantified the global methylation status of cfDNA in plasma extracted from colorectal cancer (CRC) patients, and investigated its clinical usefulness as a biomarker. LINE-1 hypomethylation index (LHI) in plasma may have a potential to serve as a biomarker enabling us to detect CRC patient at early stage. By means of the biopsy specimen, early onset of LINE-1 demethylation during adenomatous change of colorectal epithelial cells and LINE-1 demethylation progression is linear to TNM stage progression are demonstrated. LINE-1 hypomethylation is also detected from the material of the feces and regarding the utilization of this specimen, further analyses of the data are necessary.

Free Research Field

大腸がん